Secondary prevention of peripheral arterial disease

Critical Ischaemia

Volumn 11, Issue 2, 2001, Pages 37-44+36

  Bouchier Hayes, D ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FISH OIL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINE; PENTOXIFYLLINE;

ARTERY DISEASE; ATHEROSCLEROSIS; DIABETES MELLITUS; DIET; EXERCISE; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SIDE EFFECT; SMOKING CESSATION; TRANSIENT ISCHEMIC ATTACK;

EID: 0034905112     PISSN: 09562257     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: A critical review
2. The arterial organ in cardiovascular disease: ADAPT (arterial disease assessment, prevention, and treatment) clinic
3. The arterial organ in cardiovascular disease
4. Cigarette smoking, cardiovascular disease and stroke
5. How effective is nicotine replacement in helping people to stop smoking?
6. The effectiveness of the nicotine patch for smoking cessation
7. British Hypertension Society guidelines for hypertension management
8. What cardiologists need to know about diabetes
9. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus
10. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
11. The impact of cardiovascular disease on people with diabetes
12. Scandinavian Simvastatin Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
13. Prevention of coronary heart disease in men with hypercholesterolaemia
14. Pravastatin, lipids and atherosclerosis in the carotid artery
15. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction
16. Dietary management of peripheral vascular disease
17. Antiatherothrombotic properties of statins
18. Exercise therapy or angioplasty?
19. Exercise training versus angioplasty for stable claudication
20. Exercise training for claudicants
21. Exercise training and peripheral vascular disease
22. Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes
23. Claudication-inducing exercise and markers of endothelial injury
24. Role of heat shock protein 70 in vascular disease
25. Obesity: Impact on cardiovascular disease
26. Dietary guidelines for healthy American adults. A statement for health professionals from the Nutrition Committee, American Heart Association
27. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction results of the GISSI-Prevenzione trial
28. Fish oils in the prevention of atherosclerosis
29. Fish consumption and risk of sudden cardiac death
30. Antioxidant consumption and risk of coronary heart disease: Emphasis on vitamin C, vitamin E, and beta-carotene: A statement for healthcare professionals from the American Heart Association
31. Lack of effect of long term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease
32. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction
33. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)
34. Plasma homocysteine as a risk factor for vascular disease
35. Homocyst(e)ine, diet, and cardiovascular diseases: A statement for healthcare professionals from the Nutrition Committee, American Heart Association
36. Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American Heart Association
37. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
38. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes
39. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
40. Hormone replacement therapy and peripheral arterial disease: The Rotterdam study
41. Management of intermittent claudication with pentoxifylline: Meta-analysis of randomized controlled trials
42. Pharmacological management of intermittent claudication: A meta-analysis of randomised trials
43. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial
44. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial